Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2010.11.046PMID 21169024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

  2023cited by this paper
• Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation.

  2010cited by this paper
• Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells

  2010cited by this paper
• Chitosan-graft poly(p-dioxanone) copolymers: preparation, characterization, and properties.

  2009cited by this paper
• HPMA-based polymer conjugates with drug combination.

  2009cited by this paper
• Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.

  2009cited by this paper
• Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

  2009cited by this paper
• In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B

  2009cited by this paper
• Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells

  2009cited by this paper
• Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.

  2009cited by this paper
• Synthesis of radiolabeled cytarabine conjugates.

  2009cited by this paper
• Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

  2008cited by this paper
• Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples

  2008cited by this paper
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

  2008cited by this paper
• Immunomodulatory Effect of Three-Day Continuous Administration of Clarithromycin for Experimental Sepsis Due to Multidrug-Resistant Pseudomonas aeruginosa

  2008cited by this paper
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes.

  2008cited by this paper
• Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation.

  2008cited by this paper
• Reversal of Multidrug Resistance by Synthetic and Natural Compounds in Drug-Resistant MCF-7 Cell Lines

  2008cited by this paper
• The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested.

  2008cited by this paper
• In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.

  2008cited by this paper
• Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer

  2008cited by this paper
• Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer

  2008cited by this paper
• A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.

  2007cited by this paper
• The 6‐maleimidocaproyl hydrazone derivative of doxorubicin (DOXO‐EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage

  2007cited by this paper
• Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.

  2007cited by this paper
• Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin

  2007cited by this paper
• Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin

  2007cited by this paper
• Active nanodiamond hydrogels for chemotherapeutic delivery.

  2007cited by this paper
• Comparative validation of amisulpride determination in pharmaceuticals by several chromatographic, electrophoretic and spectrophotometric methods.

  2007cited by this paper
• A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance

  2007cited by this paper
• Ongoing phase I and II studies of novel anthracyclines

  2007cited by this paper
• Quantitative analysis of phenobarbital in dosage form by thin-layer chromatography combined with densitometry.

  2006cited by this paper
• High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media.

  2006cited by this paper
• Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice

  2006cited by this paper
• Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors.

  2006cited by this paper
• Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry.

  2006cited by this paper
• In-vitro and in-vivo anti-cancer activity of a novel gemcitabine–cardiolipin conjugate

  2006cited by this paper
• Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.

  2006cited by this paper
• Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics

  2006cited by this paper
• Comparative Pharmacokinetics and Metabolic Pathway of Gemcitabine During Intravenous and Intra-arterial Delivery in Unresectable Pancreatic Cancer Patients

  2005cited by this paper
• Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma

  2005cited by this paper
• Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002).

  2005cited by this paper
• Lipid nucleoside conjugates for the treatment of cancer.

  2005cited by this paper
• Inhibition of P‐glycoprotein and increasing of drug‐sensitivity of a human carcinoma cell line (KB‐A‐1) by an antisense oligodeoxynucleotide–doxorubicin conjugate in vitro

  2005cited by this paper
• Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

  2005cited by this paper
• A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

  2005cited by this paper
• Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.

  2005cited by this paper
• Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts

  2004cited by this paper
• A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate.

  2004cited by this paper
• Differences in the Intracellular Distribution of Acid-Sensitive Doxorubicin-Protein Conjugates in Comparison to Free and Liposomal Formulated Doxorubicin as Shown by Confocal Microscopy

  2004cited by this paper
• Enhancement of the p27Kip1‐mediated antiproliferative effect of trastuzumab (Herceptin) on HER2‐overexpressing tumor cells

  2004cited by this paper
• In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate.

  2004cited by this paper
• Comparison of the Usefulness of the MTT, ATP, and Calcein Assays to Predict the Potency of Cytotoxic Agents in Various Human Cancer Cell Lines

  2004cited by this paper
• HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.

  2003cited by this paper
• BR96–DOX Immunoconjugate Targeting of Chemotherapy in Brain Tumor Models

  2003cited by this paper
• Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.

  2003cited by this paper
• Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin.

  2003cited by this paper
• Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside.

  2003cited by this paper
• HPLC-MS/MS determination of a peptide conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and doxorubicin, in dog and rat plasma.

  2003cited by this paper
• Effect of Antigenic Heterogeneity on the Efficacy of Enhanced Delivery of Antibody-targeted Chemotherapy in a Human Lung Cancer Intracerebral Xenograft Model in Rats

  2003cited by this paper
• Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.

  2003cited by this paper
• Cytotoxic and Antitumor Activities of Doxorubicin Conjugates with the Epidermal Growth Factor and its Receptor-binding Fragment

  2002cited by this paper
• Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Separation of N-alkyl phenothiazine sulfones by HPTLC using an optimum mobile phase.

  2002cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Oxidative degradation study of nitrendipine using stability indicating, HPLC, HPTLC and spectrophotometric method.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.

  2001cited by this paper
• Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model

  2001cited by this paper
• Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

  2000cited by this paper
• A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma.

  2000cited by this paper
• Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.

  1999cited by this paper
• Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen.

  1999cited by this paper
• Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.

  1999cited by this paper
• Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution.

  1999cited by this paper
• Selective Protection of 2',2'-Difluorodeoxycytidine (Gemcitabine).

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Covalent bonding of PMMA, PBMA, and poly(HEMA)to hydroxyapatite particles.

  1998cited by this paper
• High performance thin-layer chromatographic method for the determination of sparfloxacin in human plasma and its use in pharmacokinetic studies.

  1998cited by this paper
• Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy.

  1998cited by this paper
• Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis

  1998cited by this paper
• Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

  1998cited by this paper
• Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil.

  1998cited by this paper
• HPTLC assay of cephalexin and cefaclor in pharmaceuticals.

  1998cited by this paper
• Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin.

  1998cited by this paper
• Synthesis and stability of four maleimide derivatives of the anticancer drug doxorubicin for the preparation of chemoimmunoconjugates

  1997cited by this paper
• Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.

  1997cited by this paper
• Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.

  1997cited by this paper
• Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative.

  1996cited by this paper
• Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas.

  1996cited by this paper
• Analysis of monoclonal antibody and immunoconjugate digests by capillary electrophoresis and capillary liquid chromatography.

  1996cited by this paper
• Determination of 2-chloro-2'-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography.

  1996cited by this paper
• Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.

  1996cited by this paper
• Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma.

  1995cited by this paper
• Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro.

  1995cited by this paper
• Anti-tumor activity of CC49-doxorubicin immunoconjugates.

  1995cited by this paper
• Internalization of an intact doxorubicin immunoconjugate

  1994cited by this paper

• Synthesis, biological evaluation and molecular docking studies of novel di-hydropyridine analogs as potent antioxidants.

  2019cites this paper
• Synthesis, Biological Evaluation and Molecular Docking Studies of Novel Di-hydropyridine Analogs as Potent Antioxidants.

  2019cites this paper
• Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

  2018cites this paper
• Carnosic acid, Tangeretin, and Ginkgolide-B Anti-Neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).

  2018cites this paper
• Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

  2018cites this paper
• Characterization of Paraoxon-ethyl and Parathion-ethyl Complexes with β-Cyclodextrin Modified Zirconium Oxide Thin Films by Infrared Spectroscopy

  2016cites this paper
• Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160

  2016cites this paper
• Dexamethasone-( c 21-phosphoramide )-[ anti-egFr ] : molecular design , synthetic organic chemistry reactions , and antineoplastic cytotoxic potency against pulmonary adenocarcinoma ( a 549 )

  2016cites this paper
• Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)

  2016cites this paper
• Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

  2016cites this paper
• Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine

  2015influential citation
• Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models

  2015cites this paper
• Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).

  2015influential citation
• Simple and rapid colorimetric detection of p-nitrophenyl substituent organophosphorous nerve agents

  2015cites this paper
• Journal of Pharmaceutics & Drug Delivery Research

  2015influential citation
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• Fabrication of Polymerized Crystalline Colloidal Array Thin Film Modified β-Cyclodextrin Polymer for Paraoxon-ethyl and Parathion-ethyl Detection

  2014cites this paper
• Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole

  2013influential citation
• Tailored immunoconjugate therapy depending on a quantity of tumor stroma

  2013cites this paper
• Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3)

  2013cites this paper
• Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.

  2013cites this paper
• Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on the Nature of Tumor Stroma

  2013cites this paper
• Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

  2012cites this paper
• Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic An

  2012influential citation
• Synthesis of a Covalent Epirubicin-(C3-amide)-Anti-HER2/neu Immunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate

  2012cites this paper